Micrococcin P2 Targets Clostridioides difficile.
J Nat Prod
; 85(8): 1928-1935, 2022 08 26.
Article
en En
| MEDLINE
| ID: mdl-35816693
ABSTRACT
Clostridioides difficile infection is a global public health threat. Extensive in vitro assays using clinical isolates have identified micrococcin P2 (MP2, 1) as a particularly effective anti-C. difficile agent. MP2 possesses a mode of action that differs from other antibiotics and pharmacokinetic properties that render it especially promising. Its time-kill studies have been investigated using hypervirulent C. difficile ribotype 027. DSS (dextran sulfate sodium)-induced in vivo mouse studies with that strain indicate that 1 is better than vancomycin and fidaxomicin. Thus, micrococcin P2 is a valuable platform to be exploited for the development of new anti-C. difficile antibiotics.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Clostridioides difficile
Límite:
Animals
Idioma:
En
Revista:
J Nat Prod
Año:
2022
Tipo del documento:
Article